Clinical trials Below are current clinical trials.453 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. Establishment of Preclinical Models from Patients with Gynecological Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz. Effective treatments for recurrent gynecological cancer are lacking, and there is a need for novel therapeutic options. One of the barriers to improving outcomes in this subgroup of patients is the paucity of tumor models that can mimic patient characteristics to study novel therapies. Patient-derived xenograft (PDX) models are considerate the most representative pre-clinical model of human cancer, recapitulating the key characteristics of the original patient tumor. Other preclincal models to test drug effcicacy includes ex vivo 3D culture and 2D culture systems. In this study, we make and test preclinical models of gynecological cancers (ovarian, fallopian tube, peritoneal, uterine, vulvar, cervix, and vaginal) of any histologic subtype using surplus tumor specimens obtained at the time of routine tumor biopsy procedure, or clinically-indicated surgery. Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy. A Study to Assess Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally-advanced Breast Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the impact of blood collection tube type and processing methods on ctDNA, evaluate the impact of long-term storage of plasma and extracted DNA, and evaluate ctDNA levels at baseline and during treatment for patients with Stage I-III breast cancer. 3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer Rochester, Minn. The overall goal of this project is to study a new 3D ultrasound imaging technology for evaluation of axillary lymph nodes in patients with breast cancer. A Study to Evaluate the Feasibility of Intraoperative Microdialysis (tissue sampling) during Neurosurgery for Central Nervous System Malignancies Rochester, Minn. Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. A Study to Compare Stereotactic Radiosurgery to Hippocampal-Avoidant Whole Brain Radiotherapy Rochester, Minn., Jacksonville, Fla. The purpose of this study is to compare stereotactic radiosurgery (SRS) to whole brain radiotherapy (WBRT) in patients with 5 or more brain metastases. A Study to See if the Depth of Tumor Invasion of Esophageal Carcinoma Predicts Lymph Node Involvement and Cancer Free Survival Rochester, Minn. The purpose of this study is to see if different depths of submucosal tumor invasion in esophageal cancer can predict lymph node involvement and survival. Patient Derived Preclinical Models Rochester, Minn. The objective of this study is to collect tumor specimens (tumor tissues, matched normal tissue when possible, and 50 mL of blood) that may inform cancer biology to eventually improve outcomes for patients with cancer. Additionally, relevant specimens that were previously collected under an IRB approved protocol (13-000942), will be used with approval of the PI of that protocol and patient consent for participation in this protocol. The collected tissue specimens will be used to develop preclinical models; i.e., cell lines, patient derived micro-cancer models as well as patient-derived xenograft models. In this study we may profile tumors using genomic and/or proteomic approaches to identify targetable alterations in tumor tissue from patients. To assure that the derived cell lines and micro-cancer models have not been cross contaminated during development with other models in development, DNA sequencing may be used. Using these preclinical models, we will test new therapies in vitro, or in vivo in mice in order to identify novel therapeutics as well as interrogate genes for their role in tumor biology. Guidance for molecular targeted therapy will involve gene analysis of oncogenes and tumor suppressor genes. Results from these studies may provide the rationale for the design of future novel clinical trials. The evaluation of these preclinical models may lead to predictive value related to patient response to therapy as well as clinical trials. With consent, these models may be shared with other investigators internal or external to Mayo Clinic. ALPN-202 With PD-1 Inhibition in Advanced Malignancies Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to evaluate ALPN-202 with PD-1 inhibition to treat adults with advanced solid tumors or lymphoma. Pagination Clinical studies PrevPrevious Page Go to page 2121 Go to page 2222 Go to page 2323 Go to page 2424 Go to page 2525 NextNext Page Request an appointment Expertise & rankingsResearch Dec. 24, 2024 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation for 2024-2025 by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 Medical Departments & Centers Oncology (Medical)